Original source: sciencedaily.com — Alzheimer’s may start shrinking two brain regions years before memory loss
Scientists at Johns Hopkins University have identified two brain regions that begin to shrink years before memory loss appears in Alzheimer’s disease. According to sciencedaily.com, tissue loss in the entorhinal cortex and amygdala can be detected up to a decade before the hippocampus—the area most commonly examined for early signs of the disease—shows similar changes.
What happened
The Johns Hopkins team examined hundreds of brain scans, including magnetic resonance imaging (MRI) and positron emission tomography (PET) scans, from two major research projects: the Alzheimer’s Disease Neuroimaging Initiative and the Biomarkers of Cognitive Decline Among Normal Individuals study. Their analysis included people at various stages of Alzheimer’s, from those without symptoms to patients who ultimately died from the disease.
They found a consistent pattern: the entorhinal cortex and amygdala, regions involved in memory and emotion, showed greater tissue loss during the earliest phases of Alzheimer’s than the hippocampus. These findings were recently published in NeuroImage Reports and presented at Neuroscience 2026, the annual meeting of the Society for Neuroscience.
The entorhinal cortex helps retrieve stored memories, while the amygdala processes emotional memories. According to the researchers, shrinkage in these regions could serve as an early warning sign of Alzheimer’s, potentially appearing five to ten years before clinical symptoms like forgetfulness or confusion.
The study also found that areas of gray matter shrinkage overlapped with regions showing abnormal changes in tau—a protein closely linked to Alzheimer’s. Normally, tau helps maintain nerve cell structure, but in Alzheimer’s it forms tangles that disrupt brain function. Using PET imaging and digital pathology, the team observed that tissue loss in the entorhinal cortex and amygdala coincided with tau-related changes.
Senior author Michael Miller, a biomedical engineer at Johns Hopkins, said, “We have found that there are early changes in the brain manifesting the clinical biomarkers of atrophy as much as a decade before there are clinical symptoms.” Co-author Marilyn Albert, director of the Johns Hopkins Alzheimer’s Disease Research Center, added, “Our goal is to be able to treat individuals before the symptoms of Alzheimer’s disease develop so that they may be delayed or even stopped.”
The researchers emphasize that more work is needed before these findings can be used as a clinical test. Their next steps include studying the molecular changes around tau accumulation in these brain regions to identify new therapy targets.
Why it matters for researchers
This discovery signals a shift in the search for early Alzheimer’s biomarkers. For neuroscience and mental health researchers, it highlights the value of examining less-studied brain regions and integrating imaging with molecular pathology. The findings may influence future research priorities, funding, and industry interest in early diagnostics and preventive therapies. With brain imaging technologies becoming more accessible, startups and established companies may seek new tools for risk stratification and early intervention—potentially expanding career options in translational neuroscience and biomarker development.
Where to dig deeper
- Read the original summary at sciencedaily.com
- Track new papers on neuroscience with Seamless
- Follow updates from the Society for Neuroscience and NeuroImage Reports for related studies
This article summarises public reporting. Facts as reported by sciencedaily.com; read the original for full details.